BGNE logo

BeiGene, Ltd. American Depositary Shares

BGNE

BGNE: BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

more

Show BGNE Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of BGNE by members of U.S. Congress

Politician Type Traded
Daniel Goldman House / D Sale $1,001 - $15,000 Jul. 12, 2023
Daniel Goldman House / D Sale $1,001 - $15,000 Jul. 10, 2023
Greg Gianforte House / R Purchase $1,001 - $15,000 Nov. 13, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BGNE's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $90,000 Apr 20, 2022 Issue: Health Issues
  • $80,000 Jan 20, 2022 Issue: HEALTH ISSUES
  • $80,000 Oct 20, 2021 Issue: HEALTH ISSUES
  • $80,000 Jul 19, 2021 Issue: HEALTH ISSUES
  • $80,000 Apr 20, 2021 Issue: HEALTH ISSUES
  • $80,000 Jan 20, 2021 Issue: None
  • $40,000 Oct 20, 2020 Issue: None
  • $20,000 Jul 20, 2020 Issue: Health Issues
  • $50,000 Apr 17, 2020 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3k δ inhibitors Aug. 15, 2023
  • Patent Title: Interoperable platform for reducing redundancy in medical database management Apr. 25, 2023
  • Patent Title: Immunotherapy for hepatocellular carcinoma Mar. 07, 2023
  • Patent Title: Crystalline forms of (s)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof Jan. 17, 2023
  • Patent Title: Anti-pd-l1 antibodies and their use as therapeutics and diagnostics Nov. 29, 2022
  • Patent Title: Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist Oct. 18, 2022
  • Patent Title: Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases Oct. 18, 2022
  • Patent Title: Bcl-2 inhibitors Aug. 23, 2022
  • Patent Title: Interoperable platform for reducing redundancy in medical database management Jul. 19, 2022
  • Patent Title: Btk inhibitors with improved dual selectivity Jul. 05, 2022
  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors Jan. 11, 2022
  • Patent Title: Anti-tigit antibodies and their use as therapeutics and diagnostics Jan. 04, 2022
  • Patent Title: Anti-tim-3 antibodies and use thereof Dec. 21, 2021
  • Patent Title: Treatment cancers using a combination comprising parp inhibitors Dec. 21, 2021
  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3k δ inhibitors Oct. 05, 2021
  • Patent Title: Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof Jan. 26, 2021
  • Patent Title: 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases Jan. 05, 2021
  • Patent Title: Combination of a pd-1 antagonist and a raf inhibitor for treating cancer Dec. 15, 2020
  • Patent Title: 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases May. 12, 2020
  • Patent Title: Fused tricyclic compounds as raf kinase inhibitors Mar. 03, 2020
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Feb. 18, 2020
  • Patent Title: Anti-pd-l1 antibodies and their use as therapeutics and diagnostics Jan. 28, 2020
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Dec. 10, 2019
  • Patent Title: Process for preparing a parp inhibitor, crystalline forms, and uses thereof Oct. 29, 2019
  • Patent Title: Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore Jul. 16, 2019
  • Patent Title: 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases May. 07, 2019
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Feb. 19, 2019
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Oct. 30, 2018
  • Patent Title: Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators Jun. 26, 2018
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Mar. 20, 2018
  • Patent Title: Fused tricyclic compounds as raf kinase inhibitors Feb. 20, 2018
  • Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics Dec. 05, 2017
  • Patent Title: Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Nov. 28, 2017
  • Patent Title: Fused tricyclic amide compounds as multiple kinase inhibitors Jun. 06, 2017
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Jun. 06, 2017
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Apr. 11, 2017
  • Patent Title: Substituted imidazo[1,2-b]pyrazoles as bruton's tyrosine kinase modulators Jan. 31, 2017
  • Patent Title: Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators Sep. 20, 2016
  • Patent Title: Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Jul. 19, 2016
  • Patent Title: Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as parp inhibitors May. 03, 2016
  • Patent Title: Fused tricyclic compounds as raf kinase inhibitors Mar. 01, 2016
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Feb. 16, 2016
  • Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics Dec. 22, 2015
  • Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics May. 27, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of BGNE in WallStreetBets Daily Discussion

BGNE News

Recent insights relating to BGNE

CNBC Recommendations

Recent picks made for BGNE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BGNE

Corporate Flights

Flights by private jets registered to BGNE